TD Asset Management
ESPR icon

TD Asset Management’s Esperion Therapeutics ESPR Stock Holding History

TD Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,900
Closed -$508K – 1363
2020
Q2 		$508K Buy
9,900
+400
+4% +$16.7K ﹤0.01% 1211
2020
Q1 		$300K Buy
+9,500
New +$501K ﹤0.01% 1266

Other funds holding ESPR

Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

TD Asset Management's ESPR Position: Q3 2020 in Review

TD Asset Management sold out of Esperion Therapeutics (ESPR) in Q3 2020, closing a stake of 9,900 shares — an estimated $508K sold.

TD Asset Management first reported a position in ESPR in Q1 2020 and held it in 2 quarters. The position peaked at $508K in Q2 2020. 167 funds tracked by Wall St. Rank hold ESPR as of Q3 2020.

  • TD Asset Management reported no remaining Esperion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • TD Asset Management sold 9,900 Esperion Therapeutics shares in Q3 2020, an estimated $508K.
  • TD Asset Management first reported a position in Esperion Therapeutics in Q1 2020 and held it in 2 quarters.
  • TD Asset Management's Esperion Therapeutics position peaked at $508K in Q2 2020.
  • 167 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2020.

Based on TD Asset Management's 13F filing for Q3 2020, filed 10 Nov 2020.